Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Leonie C.H. Wong is active.

Publication


Featured researches published by Leonie C.H. Wong.


Europace | 2014

Sudden unexplained death in infants and children: the role of undiagnosed inherited cardiac conditions

Leonie C.H. Wong; Elijah R. Behr

Sudden unexplained death in childhood is a traumatic event for both the immediate family and medical professionals. This is termed sudden unexplained or arrhythmic death syndrome (SUDS/SADS) for children over 1 year of age while sudden unexplained death in infancy or sudden infant death syndrome (SUDI/SIDS) refers to unexplained deaths in the first year of life. There is increasing evidence for the role of undiagnosed inherited cardiac conditions, particularly channelopathies, as the cause of these deaths. This has far-reaching implications for the family regarding the potential risk to other family members and future pregnancies, providing a challenge not only in the counselling but also in the structured assessment and management of immediate relatives. This review will discuss the cardiac risk involved in sudden unexplained deaths of infants and children, the role of molecular autopsy, family cardiological screening, current management strategies, and future directions in this area.


Circulation-arrhythmia and Electrophysiology | 2014

Cardiac Evaluation of Pediatric Relatives in Sudden Arrhythmic Death Syndrome A 2-Center Experience

Leonie C.H. Wong; Ferran Roses-Noguer; Janice A. Till; Elijah R. Behr

Background—Sudden arrhythmic death syndrome defines a sudden unexpected and unexplained death despite comprehensive pathological and toxicological investigation. Previous studies have focused on evaluation of adult relatives. There is, however, a lack of data in children, leading to highly variable management. We sought to determine the clinical utility of cardiac evaluation in pediatric relatives of sudden arrhythmic death syndrome probands. Methods and Results—Retrospective review was undertaken of pediatric patients with a family history of sudden arrhythmic death syndrome assessed from 2010 to 2013 in 2 centers. Clinical history, cardiac, and genetic investigations were assessed, including diagnoses made after evaluation of adult relatives. A total of 112 pediatric relatives from 61 families were evaluated (median age at presentation, 8 years; range, 0.5–16 years). A probable diagnosis was made in 18 (29.5%) families: Brugada syndrome, 13/18 (72%); long QT syndrome, 3/18 (17%); and catecholaminergic polymorphic ventricular tachycardia, 2/18 (11%). Genetic testing identified mutations in 20% of Brugada syndrome (2/10) and 50% of long QT syndrome (1/2) and catecholaminergic polymorphic ventricular tachycardia families (1/2) who were tested. Pediatric evaluation diagnosed 6/112 relatives (5.4%), increasing to 7% (6/85) if only first-degree relatives were assessed. The only useful diagnostic tests were the 12-lead and exercise electrocardiograms and ajmaline provocation test. The median duration of follow-up was 2.1 years (range, 0.2–8.2 years) with no cardiac events. Conclusions—The yield of evaluating pediatric relatives is significant and higher when focused on first-degree relatives and on conditions usually expressed in childhood. We propose a management pathway for these children.


The Lancet | 2018

Dysfunction of NaV1.4, a skeletal muscle voltage-gated sodium channel, in sudden infant death syndrome: a case-control study

Roope Männikkö; Leonie C.H. Wong; David J. Tester; Michael G. Thor; R. Sud; Dimitri M. Kullmann; Mary G. Sweeney; Costin Leu; Sanjay M. Sisodiya; David Fitzpatrick; Margaret Evans; Iona Jeffrey; Jacob Tfelt-Hansen; Marta C. Cohen; Peter J Fleming; Amie Jaye; Michael A. Simpson; Michael J. Ackerman; Michael G. Hanna; Elijah R. Behr; E. Matthews

Summary Background Sudden infant death syndrome (SIDS) is the leading cause of post-neonatal infant death in high-income countries. Central respiratory system dysfunction seems to contribute to these deaths. Excitation that drives contraction of skeletal respiratory muscles is controlled by the sodium channel NaV1.4, which is encoded by the gene SCN4A. Variants in NaV1.4 that directly alter skeletal muscle excitability can cause myotonia, periodic paralysis, congenital myopathy, and myasthenic syndrome. SCN4A variants have also been found in infants with life-threatening apnoea and laryngospasm. We therefore hypothesised that rare, functionally disruptive SCN4A variants might be over-represented in infants who died from SIDS. Methods We did a case-control study, including two consecutive cohorts that included 278 SIDS cases of European ancestry and 729 ethnically matched controls without a history of cardiovascular, respiratory, or neurological disease. We compared the frequency of rare variants in SCN4A between groups (minor allele frequency <0·00005 in the Exome Aggregation Consortium). We assessed biophysical characterisation of the variant channels using a heterologous expression system. Findings Four (1·4%) of the 278 infants in the SIDS cohort had a rare functionally disruptive SCN4A variant compared with none (0%) of 729 ethnically matched controls (p=0·0057). Interpretation Rare SCN4A variants that directly alter NaV1.4 function occur in infants who had died from SIDS. These variants are predicted to significantly alter muscle membrane excitability and compromise respiratory and laryngeal function. These findings indicate that dysfunction of muscle sodium channels is a potentially modifiable risk factor in a subset of infant sudden deaths. Funding UK Medical Research Council, the Wellcome Trust, National Institute for Health Research, the British Heart Foundation, Biotronik, Cardiac Risk in the Young, Higher Education Funding Council for England, Dravet Syndrome UK, the Epilepsy Society, the Eunice Kennedy Shriver National Institute of Child Health & Human Development of the National Institutes of Health, and the Mayo Clinic Windland Smith Rice Comprehensive Sudden Cardiac Death Program.


Europace | 2012

Acquired long QT syndrome: as risky as congenital long QT syndrome?

Leonie C.H. Wong; Elijah R. Behr

This editorial refers to ‘Role of implantable cardioverter defibrillator therapy in patients with acquired long QT syndrome: A long-term follow-up’ by G. Monnig et al ., on page 396 Long QT syndrome (LQTS) describes a group of disorders characterized by QT interval prolongation secondary to delayed cardiac repolarization that may either be genetic (otherwise known as ‘congenital’) or acquired. The substrate of abnormal cardiac repolarization predisposes to development of torsades de pointes (TdP), the characteristic form of polymorphic ventricular tachycardia, and cardiac arrest. Congenital LQTS has a population prevalence of 1 in 2000 and is caused by mutations in genes coding for cardiac ion channels and their channel interacting proteins. Delayed cardiac repolarization results mainly from loss-of-function mutations affecting rectifying potassium currents (IKs, IKr, and IK1) or gain-of-function mutations affecting the inward sodium current and rarely the L-type calcium current. Acquired LQTS has traditionally been associated with exposure to QT prolonging drugs, with antiarrhythmic medications being the most common precipitant. The main mechanism of drug-induced LQTS involves the inhibition of IKr in a similar fashion to that seen in the LQT2 subtype of congenital LQTS which arises from loss-of-function mutations in human ether-a-go-go-related gene which encodes the alpha subunit of IKr.1,2Both are associated with pause-dependent TdP. Other acute causes include electrolyte imbalance (in particular, hypokalaemia), after reversion of atrial fibrillation and transient bradyarrhythmia. There are also established chronic predisposing factors such as structural and cardiac conduction disease, metabolic and endocrine abnormalities. There is, however, a growing body of …


European Heart Journal | 2018

SCN5A mutations in 442 neonates and children: genotype–phenotype correlation and identification of higher-risk subgroups

Alban-Elouen Baruteau; Florence Kyndt; Elijah R. Behr; Arja S Vink; Matthias Lachaud; Anna Joong; Jean-Jacques Schott; Minoru Horie; Isabelle Denjoy; Lia Crotti; Wataru Shimizu; Johan Martijn Bos; Elizabeth A. Stephenson; Leonie C.H. Wong; Dominic Abrams; Andrew M. Davis; Annika Winbo; Anne M. Dubin; Shubhayan Sanatani; Leonardo Liberman; Juan Pablo Kaski; Boris Rudic; Sit Yee Kwok; Claudine Rieubland; Jacob Tfelt-Hansen; George F. Van Hare; Béatrice Guyomarc’h-Delasalle; Nico A. Blom; Yanushi D. Wijeyeratne; Jean-Baptiste Gourraud

Aims To clarify the clinical characteristics and outcomes of children with SCN5A-mediated disease and to improve their risk stratification. Methods and results A multicentre, international, retrospective cohort study was conducted in 25 tertiary hospitals in 13 countries between 1990 and 2015. All patients ≤16 years of age diagnosed with a genetically confirmed SCN5A mutation were included in the analysis. There was no restriction made based on their clinical diagnosis. A total of 442 children {55.7% boys, 40.3% probands, median age: 8.0 [interquartile range (IQR) 9.5] years} from 350 families were included; 67.9% were asymptomatic at diagnosis. Four main phenotypes were identified: isolated progressive cardiac conduction disorders (25.6%), overlap phenotype (15.6%), isolated long QT syndrome type 3 (10.6%), and isolated Brugada syndrome type 1 (1.8%); 44.3% had a negative electrocardiogram phenotype. During a median follow-up of 5.9 (IQR 5.9) years, 272 cardiac events (CEs) occurred in 139 (31.5%) patients. Patients whose mutation localized in the C-terminus had a lower risk. Compound genotype, both gain- and loss-of-function SCN5A mutation, age ≤1 year at diagnosis in probands and age ≤1 year at diagnosis in non-probands were independent predictors of CE. Conclusion In this large paediatric cohort of SCN5A mutation-positive subjects, cardiac conduction disorders were the most prevalent phenotype; CEs occurred in about one-third of genotype-positive children, and several independent risk factors were identified, including age ≤1 year at diagnosis, compound mutation, and mutation with both gain- and loss-of-function.


Genetics in Medicine | 2018

Noncardiac genetic predisposition in sudden infant death syndrome

Belinda Gray; David J. Tester; Leonie C.H. Wong; Pritha Chanana; Amie Jaye; Jared M. Evans; Alban-Elouen Baruteau; Margaret Evans; Peter J Fleming; Iona Jeffrey; Marta C. Cohen; Jacob Tfelt-Hansen; Michael A. Simpson; Michael J. Ackerman; Elijah R. Behr

PurposeSudden infant death syndrome (SIDS) is the commonest cause of sudden death of an infant; however, the genetic basis remains poorly understood. We aimed to identify noncardiac genes underpinning SIDS and determine their prevalence compared with ethnically matched controls.MethodsUsing exome sequencing we assessed the yield of ultrarare nonsynonymous variants (minor allele frequency [MAF] ≤0.00005, dominant model; MAF ≤0.01, recessive model) in 278 European SIDS cases (62% male; average age =2.7 ± 2 months) versus 973 European controls across 61 noncardiac SIDS-susceptibility genes. The variants were classified according to American College of Medical Genetics and Genomics criteria. Case-control, gene-collapsing analysis was performed in eight candidate biological pathways previously implicated in SIDS pathogenesis.ResultsOverall 43/278 SIDS cases harbored an ultrarare single-nucleotide variant compared with 114/973 controls (15.5 vs. 11.7%, p=0.10). Only 2/61 noncardiac genes were significantly overrepresented in cases compared with controls (ECE1, 3/278 [1%] vs. 1/973 [0.1%] p=0.036; SLC6A4, 2/278 [0.7%] vs. 1/973 [0.1%] p=0.049). There was no difference in yield of pathogenic or likely pathogenic variants between cases and controls (1/278 [0.36%] vs. 4/973 [0.41%]; p=1.0). Gene-collapsing analysis did not identify any specific biological pathways to be significantly associated with SIDS.ConclusionsA monogenic basis for SIDS amongst the previously implicated noncardiac genes and their encoded biological pathways is negligible.


Circulation-arrhythmia and Electrophysiology | 2014

Cardiac Evaluation of Pediatric Relatives in Sudden Arrhythmic Death SyndromeCLINICAL PERSPECTIVE: A 2-Center Experience

Leonie C.H. Wong; Ferran Roses-Noguer; Janice A. Till; Elijah R. Behr

Background—Sudden arrhythmic death syndrome defines a sudden unexpected and unexplained death despite comprehensive pathological and toxicological investigation. Previous studies have focused on evaluation of adult relatives. There is, however, a lack of data in children, leading to highly variable management. We sought to determine the clinical utility of cardiac evaluation in pediatric relatives of sudden arrhythmic death syndrome probands. Methods and Results—Retrospective review was undertaken of pediatric patients with a family history of sudden arrhythmic death syndrome assessed from 2010 to 2013 in 2 centers. Clinical history, cardiac, and genetic investigations were assessed, including diagnoses made after evaluation of adult relatives. A total of 112 pediatric relatives from 61 families were evaluated (median age at presentation, 8 years; range, 0.5–16 years). A probable diagnosis was made in 18 (29.5%) families: Brugada syndrome, 13/18 (72%); long QT syndrome, 3/18 (17%); and catecholaminergic polymorphic ventricular tachycardia, 2/18 (11%). Genetic testing identified mutations in 20% of Brugada syndrome (2/10) and 50% of long QT syndrome (1/2) and catecholaminergic polymorphic ventricular tachycardia families (1/2) who were tested. Pediatric evaluation diagnosed 6/112 relatives (5.4%), increasing to 7% (6/85) if only first-degree relatives were assessed. The only useful diagnostic tests were the 12-lead and exercise electrocardiograms and ajmaline provocation test. The median duration of follow-up was 2.1 years (range, 0.2–8.2 years) with no cardiac events. Conclusions—The yield of evaluating pediatric relatives is significant and higher when focused on first-degree relatives and on conditions usually expressed in childhood. We propose a management pathway for these children.


Circulation-arrhythmia and Electrophysiology | 2014

Cardiac Evaluation of Pediatric Relatives in Sudden Arrhythmic Death SyndromeCLINICAL PERSPECTIVE

Leonie C.H. Wong; Ferran Roses-Noguer; Janice A. Till; Elijah R. Behr

Background—Sudden arrhythmic death syndrome defines a sudden unexpected and unexplained death despite comprehensive pathological and toxicological investigation. Previous studies have focused on evaluation of adult relatives. There is, however, a lack of data in children, leading to highly variable management. We sought to determine the clinical utility of cardiac evaluation in pediatric relatives of sudden arrhythmic death syndrome probands. Methods and Results—Retrospective review was undertaken of pediatric patients with a family history of sudden arrhythmic death syndrome assessed from 2010 to 2013 in 2 centers. Clinical history, cardiac, and genetic investigations were assessed, including diagnoses made after evaluation of adult relatives. A total of 112 pediatric relatives from 61 families were evaluated (median age at presentation, 8 years; range, 0.5–16 years). A probable diagnosis was made in 18 (29.5%) families: Brugada syndrome, 13/18 (72%); long QT syndrome, 3/18 (17%); and catecholaminergic polymorphic ventricular tachycardia, 2/18 (11%). Genetic testing identified mutations in 20% of Brugada syndrome (2/10) and 50% of long QT syndrome (1/2) and catecholaminergic polymorphic ventricular tachycardia families (1/2) who were tested. Pediatric evaluation diagnosed 6/112 relatives (5.4%), increasing to 7% (6/85) if only first-degree relatives were assessed. The only useful diagnostic tests were the 12-lead and exercise electrocardiograms and ajmaline provocation test. The median duration of follow-up was 2.1 years (range, 0.2–8.2 years) with no cardiac events. Conclusions—The yield of evaluating pediatric relatives is significant and higher when focused on first-degree relatives and on conditions usually expressed in childhood. We propose a management pathway for these children.


Europace | 2013

Familial cardiological evaluation in sudden arrhythmic death syndrome: essential but challenging

Leonie C.H. Wong; Elijah R. Behr


Journal of the American College of Cardiology | 2018

Cardiac Genetic Predisposition in Sudden Infant Death Syndrome

David J. Tester; Leonie C.H. Wong; Pritha Chanana; Amie Jaye; Jared M. Evans; David Fitzpatrick; Margaret Evans; Peter J Fleming; Iona Jeffrey; Marta C. Cohen; Jacob Tfelt-Hansen; Michael A. Simpson; Elijah R. Behr; Michael J. Ackerman

Collaboration


Dive into the Leonie C.H. Wong's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar

Jacob Tfelt-Hansen

Copenhagen University Hospital

View shared research outputs
Top Co-Authors

Avatar

Iona Jeffrey

St George’s University Hospitals NHS Foundation Trust

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Marta C. Cohen

Boston Children's Hospital

View shared research outputs
Researchain Logo
Decentralizing Knowledge